Format

Send to

Choose Destination
Tech Coloproctol. 2004 Nov;8 Suppl 1:s56-8.

Serum levels of bcl-2 in patients with colorectal cancer.

Author information

1
1 Alexandrou Svolou, 546 22 Thessaloniki, Greece. kgiann@med.auth.gr

Abstract

BACKGROUND:

Many recent studies focus on the immunohistochemical evaluation of Bcl-2 expression, and its prognostic significance in colorectal cancer (CRC). Our aim was to investigate the presence of bcl-2 protein in the serum and to examine the association between its levels, stage and tumour load, in patients with CRC.

METHODS:

A commercially available ELISA was used for the estimation of bcl-2 levels, in 94 patients with different stages of CRC. Forty-eight healthy blood donors served as controls. Concentrations ranging 2SD above and below the controls median were accepted as "normal".

RESULTS:

bcl-2 was detected in the serum of patients with CRC. A significantly higher proportion of patients with non-metastatic disease (61%), had high serum bcl-2 values, compared to patients with metastatic disease (28%, p<0.0001).

CONCLUSIONS:

Serum bcl-2 in patients with CRC may reflect the degree of Bcl-2 expression in cancer tissue. Serum bcl-2 is easily determinable, and could be useful as a prognostic marker in CRC.

PMID:
15655644
DOI:
10.1007/s10151-004-0112-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center